Industry Briefs: Apr. 16, 2012 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Industry Briefs: Apr. 16, 2012
A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.


Company News

AMRI and Biota have agreed to develop and manufacture the influenza antiviral CS8958 (laninamivir), a second-generation, long-acting neuraminidase inhibitor. Read More

Evans Analytical Group (EAG) has acquired PTRL West and PTRL Europe. Read More

Nascent and Catalent Pharma Solutions have formed a product-development agreement for a Nascent antibody drug candidate. Read More

Pharmatek has added to its liquid encapsulation capabilities. Read More

Q Laboratories has completed construction on its 5000-ft2 microbiology research and development laboratory.

Shire has agreed to acquire Pervasis Therapeutics and related endothelial cell technology. Read More

Vanda Pharmaceuticals has acquired the rights to an NK-1 receptor antagonist from Eli Lilly. Read More

People News

Hospira has named John B. Elliot senior vice-president of operations. Read More

Penn Pharma has appointed Jerome Detreille as senior director of new business development. Read More

Michael A. Griffith has been appointed to Repligen’s board of directors. Read More

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality

Click here